Company ProfilePremium

AMBANI ORGANICS LT

Company Profile Analysis

Ticker: AMBANIORGO.NS

ESOMAR 23 Corporate BadgeISO Certifications Badge
AMBANI ORGANICS LT - Company showcase

Year Founded & Workforce

1985

124 Employees

AMBANI ORGANICS LT logo

AMBANI ORGANICS LT Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

AMBANI ORGANICS LT Overview

Ambani Orgochem is a four-decade-old, promoter-run Indian specialty-chemicals micro-cap. It is moving away from a commodity-adjacent base of water-based acrylic emulsions, binders, textile auxiliaries and metal-octoate paint driers. Its target is a "super-specialty" portfolio built on organic peroxides (polymerisation initiators and resin-curing agents) and salicylic acid with its salicylate esters (fragrance, UV-filter and pharmaceutical intermediates). Manufacturing sits at four units in MIDC Tarapur, Maharashtra, and a newer facility in Dahej, Gujarat. The Dahej plant was damaged by fire in February 2024 and restarted in February 2025. Revenue compounded at about 22–23% over five years, to ₹240.7 Cr in FY2026 and about ₹304 Cr on a trailing basis to September 2026. Profitability has lagged: EBITDA margins sit at 5–7% and net margins below 2%. The balance sheet is leveraged and working-capital heavy. The equity story now rests on Dahej ramp-up, product-mix upgrade, a capacity-led Tarapur expansion, and a pending ₹43.9 Cr preferential warrant raise.


Company's own description. In filings and press releases the company calls itself a manufacturer, processor, importer, supplier and exporter of water-based specialty chemicals. It names the paper, paint, textile, carpet and adhesive industries as customers. The FY2025 MD&A and the November 2025 press release extend the list to organic peroxides, salicylic acid and salicylic derivatives. They add pharmaceuticals, fragrances, cosmetics and home care as end markets. The company stresses "green chemistry": water-based, APEO-free and low-VOC formulations. It holds ISO 9001:2015, ISO 14001:2015 and ISO 45001:2018 certifications, plus GOTS and ZDHC certification for selected textile chemicals (FY2025 MD&A).

Independent characterisation. The company runs three economically distinct businesses under one reporting segment:

  1. Legacy water-based polymers and auxiliaries (Tarapur). This covers acrylic and styrene-acrylic emulsions, PVA/PVP-type binders, thickeners, defoamers, dispersants, textile auxiliaries and detergent formulations. These are formulation-driven, moderately differentiated and price-competitive products. They sell to paint, paper, textile, carpet, construction and adhesive manufacturers. Raw-material pass-through (acrylic monomers, styrene, butyl acrylate) is high and margins are thin. The FY2026 investor presentation, as summarised by third parties, puts acrylic coatings and adhesives capacity at about 2,000 tonnes per month. It plans about 4,500 tonnes per month after a Tarapur expansion.

  2. Metal carboxylates / paint driers and FRP accelerators (Tarapur, partly through subsidiary Om Maruti Glasswool & Wirenetting Products). Cobalt, manganese, lead, calcium, zinc, zirconium, iron, barium, cadmium, potassium and copper octoates and naphthenates, sold to paint, ink and FRP-composite makers.

  3. Peroxide and salicylate platform (Dahej, plus earlier peroxide production from 2019). About 39 organic-peroxide grades sold under the "RAA PRO" brand, plus salicylic acid and 13 salicylate esters under the "AOPL" code. These are higher-value, hazard-intensive chemistries with fewer domestic producers. They serve polymer and composite makers, solar-encapsulant (EVA) producers, rubber vulcanisers, fragrance houses, personal-care formulators and pharma.

Business model and revenue model. Revenue is essentially 100% product sales of manufactured chemicals, with some traded material. There is no subscription, licensing or service revenue. Sales are B2B, made to order or from stock, through direct sales across about 20 Indian states and exports to over 40 countries (FY2026 investor presentation, per third-party summary). Exports are material. Foreign-exchange earnings were ₹76.44 Cr in FY2025, about 40% of revenue from operations (FY2025 Directors' Report).

Value-chain position. The company is a mid-stream converter. It buys petrochemical intermediates (acrylic monomers, styrene, tert-butanol/hydrogen peroxide derivatives, MEK, phenol/sodium phenolate for salicylic acid, metal salts, 2-ethylhexanoic acid) and sells functional ingredients that make up a small share of customers' bill of materials. It does not own feedstock. This leaves it exposed to raw-material volatility, mitigated only by price pass-through with a lag.

Customer types and end markets. Paint and coatings (decorative and industrial), paper, textiles and carpets, adhesives and construction chemicals, composite FRP (boats, wind-turbine blades, tanks, marble slabs, sanitaryware), polymers and LDPE, rubber and tyres, solar-panel EVA encapsulants, fragrance and flavour, personal care (sunscreens, anti-ageing creams), home care (detergents, air care), and pharmaceuticals (pain balms, acne preparations). No customer is named publicly. Customer concentration is not publicly disclosed. Infomerics describes the clientele as diversified (rating rationale, 30 Mar 2023).

Strategy

Stated strategy (themes from the FY2026 Annual Report Chairman's message, as excerpted, and the H1 FY2026 press release).

  1. Becoming a "super-specialty" chemicals company. The FY2026 Annual Report states that strengthening its position as a super-specialty producer is a key priority, and that new molecules will strengthen its competitive position.

  2. Mix upgrade toward value-added products. The November 2025 release cites a higher share of salicylates and peroxide derivatives as a revenue and margin driver. Management says it is exploring opportunities to supply more value-added products.

  3. Dahej stabilisation and utilisation ramp. Production was improving month by month but still at partial capacity as of November 2025.

  4. Capacity-led growth at Tarapur. Acrylic coatings and adhesives capacity is to rise from about 2,000 to about 4,500 t/month. Salicylic acid is to rise from about 50 to about 200 t/month (FY2026 investor presentation).

  5. Operating efficiency. Working-capital efficiency, lower finance costs, supply-chain management and control of operating costs (November 2025 release).

  6. Green chemistry positioning. Water-based, APEO-free, low-VOC products; ISO 14001, GOTS, ZDHC certifications.

Initiatives announced in the last 24 months (October 2024 – October 2026).

Medium-term targets and guidance. Management has given no numeric revenue, margin or capex guidance. Statements are qualitative ("more meaningful improvement in margins" in coming quarters, November 2025). No cost-programme targets or quantified sustainability commitments are disclosed.

Products & Services

Pricing models are not publicly disclosed for any product. All products are sold as bulk industrial chemicals on negotiated B2B pricing. Launch years are given where disclosed.

Organic Peroxides — "RAA PRO" range (production since 2019; Dahej scale-up 2023–2025)

ProductChemistryFormActive oxygenPurity (%)Principal applications
RAA PRO TB 70 / TB 75 / TB 80Tert-butyl hydroperoxideAqueous solution12.43% / 13.33% / 14.20%70 / 75 / 80Emulsion polymerisation, resins, agrochemicals, polyester curing, propylene oxide
RAA PRO DT 98Di-tert-butyl peroxideLiquid10.70%98Emulsion polymerisation, specialty resins, fragrance, petrochemicals, LDPE
RAA PRO ME 6, ME 5 LWC, ME 5.5, ME V338, ME 6 PTFE, ME 4.5 LPT-IN, ME V395Methyl ethyl ketone peroxide (various carriers, incl. phthalate-free)Solution8.5–10%—Unsaturated polyester (UP) resin curing: buttons, wind blades, boats, marble slabs, FRP tanks
RAA PRO PB 98 / PB 93Tert-butyl peroxybenzoateLiquid / solution8.05% / 6.39–6.67%98 / 79.25UP curing, quartz marble, sanitaryware, grouts
RAA PRO TMH 98Tert-butyl peroxy-3,5,5-trimethylhexanoateLiquid6.74%97UP curing, cure-in-place pipe
RAA PRO BP 75, BP 50 (several carriers incl. DMP, DCHP, DIBP, DBP, phthalate-free)Dibenzoyl peroxidePowder / paste3.27–4.95%50–75Auto putty, chemical anchors, UP curing, flour/sugar bleaching, APIs, acne creams
RAA PRO TBEC 985 / TBEC 975Tert-butyl peroxy-2-ethylhexyl carbonateLiquid6.39% / 6.33%98.5 / 97.5Polymer production, solar-panel EVA encapsulant, crosslinking
RAA PRO CP 98Tert-butyl cumyl peroxideLiquid7.22–7.37%95.5Rubber curing, EVA encapsulant, wire and cable
RAA PRO DTADi-tert-amyl peroxideLiquid8.82%96High-solids varnishes, LDPE, acrylic polymerisation
RAA PRO TAEC / ECAC 6040Tert-amyl peroxy-2-ethylhexyl carbonate / TBEC-TAEC blendLiquid5.89% / 6.15–6.20%96 / n/aSolar EVA encapsulation, rubber vulcanisation, PVC
RAA PRO 279 / AAPAcetylacetone peroxide (blend with TBPB / straight)Liquid4.0–4.7%n/a / 34.75Resin transfer moulding, vinyl ester, roof panels, FRP pipe
RAA PRO DCP 98 / DCP 99Dicumyl peroxideCrystals5.79% / 5.85%98 / 99Rubber vulcanisation, shoe soles, tyres, EVA, thermoset composites
RAA PRO F 960 / F 40P / FMIX 3638Bis(tert-butylperoxyisopropyl)benzenePowder / liquid3.4–9.07%96 / 40 / 37Polyolefin and rubber crosslinking, UP curing
RAA PRO CH 800 / CH 470Cumyl hydroperoxideLiquid8.40% / 4.73–4.94%80 / 46Vinyl ester curing, phenol production, polymerisation catalyst
RAA PRO LP 98 / LP 99Dilauroyl peroxidePowder / flakes3.93% / 3.97%98 / 99Polymerisation initiator, acrylics, thermosets
RAA PRO MIBKMethyl isobutyl ketone peroxideLiquid9.7–10.3%—RTM, vinyl ester, UP curing

Source: company website product catalogue (accessed October 2026). Target customers: composite fabricators, polymer and LDPE producers, rubber compounders, solar-module encapsulant makers, pharma and food processors. Flagship view: the MEKP range (the volume curing agent for India's FRP industry) and the solar-EVA carbonates (TBEC/TAEC) are the most strategically relevant lines, given India's solar-module manufacturing build-out.

Salicylic Acid and Salicylates — "AOPL" range (salicylic acid plant commissioned 2023)

ProductChemistryPurityApplications
Salicylic acid——Pharma (aspirin, keratolytics), cosmetics, intermediates. Capacity planned to rise from about 50 to about 200 t/month (FY2026 presentation)
AOPL MS-99Methyl salicylate99–100.5%Pain balms, gels, liniments, flavours
AOPL OS-99Octyl salicylate≥99%UVB filter in sunscreens
AOPL BS-99Benzyl salicylate≥99%Fragrance fixative, UV absorber
AOPL CS-96Cyclohexyl salicylate≥96%Detergents, personal care, perfumes
AOPL 2EHS-992-Ethylhexyl salicylate≥99%UVB filter, anti-ageing creams
AOPL AMS-99Amyl salicylate≥99%Detergent and soap fragrance
AOPL BUS-98Butyl salicylate≥98%Cosmetics, fine fragrance, household cleaners
AOPL HEPS-98Heptyl salicylate≥98%Niche perfumery
AOPL HS-98Hexyl salicylate≥98%Detergent, air-care, cosmetic fragrance
AOPL ALLS-98Allyl salicylate≥98%Perfumes, air fresheners
AOPL IAMS-98Isoamyl salicylate≥98%Soaps, aromatherapy
AOPL IBUS-98Isobutyl salicylate≥99% (as listed)Candles, fabric softeners, detergents
AOPL PETS-98Phenyl ethyl salicylate≥98%Candles, aromatherapy

Source: company website (October 2026); FY2026 investor presentation (third-party summary). Target customers: fragrance and flavour houses, FMCG home and personal-care formulators, sunscreen makers, pharma.

Paint Driers and Metal Carboxylates — "AOPL" range (diversification from 2017)

Product familyMetal-content grades (%)Function
Cobalt octoate12, 10, 8, 6, 3Primary surface drier
Manganese octoate10, 8, 6Intermediate drier
Lead octoate36, 32, 24, 18Through drier (legacy chemistry)
Calcium octoate10, 6, 5, 3Auxiliary through drier, pigment wetting
Zinc octoate18, 12, 6Auxiliary drier, anti-wrinkle
Zirconium octoate24, 18, 12, 6Lead replacement, through drier
Copper naphthenate8.6, 8, 6Antifouling, wood and textile preservative
Iron octoate6, 4Stoving finishes
Barium octoate12Lead substitute
Cadmium octoate15.5, 15Heat stabiliser aid
Potassium octoate15Cobalt booster, UP curing, water-based coatings
Combination driersAOPL 1025, 1028, 1068, 1425, 10725, 1121, 1123, 11 N9, 1345 (Co/Mn/Pb, Co/Pb/Ca, Co/Ca/Zr, Co/Ba)Ready-to-use blends for enamels, inks, primers

Source: company website. Target customers: decorative and industrial paint makers, printing-ink producers, FRP fabricators. The accelerators category on the website covers cobalt-type FRP accelerators; individual grades were not separately catalogued.

Water-based Emulsions, Binders and Textile/Process Chemicals (legacy core)

Product lineDescriptionEnd marketSource
Acrylic emulsionsPure acrylic and butyl-acrylate-based polymersPaints, coatings, constructionIPO documents; website
Styrene-acrylic emulsionsCost-optimised bindersPaints, paper coatingIPO documents
Butyl-acrylate-based terpolymersSpecialty bindersCoatings, textilesIPO documents
PVP / PVA-type emulsions and bindersBinders and adhesivesPaper, adhesives, textilesIPO documents; Infomerics
AdhesivesWater-based adhesive polymersPackaging, wood, carpetIPO documents; website
ThickenersRheology modifiersPaints, textile printingIPO documents
Defoamers and dispersantsProcess aidsPaints, paper, textilesIPO documents
Textile auxiliariesProcessing chemicals; some GOTS/ZDHC certifiedTextile and carpetFY2025 MD&A
Detergent formulationsFormulated cleaning chemicalsIndustrial/householdIPO documents

Capacity for acrylic coatings and adhesives is about 2,000 t/month, rising to about 4,500 t/month after the Tarapur expansion (FY2026 presentation, third-party summary). Specifications and grade names for this range were not published on the website at the time of review.

Financial Narrative

Basis: standalone unless stated. ₹ Cr. Sources: Infomerics rating releases (FY2022–FY2025 audited figures), FY2025 Directors' Report and MD&A, FY2026 audited-results filing (21 May 2026), FY2026 investor presentation (third-party summary), Screener.in (filing-derived, rounded to whole crores where marked). Blank cells mean not publicly disclosed. Consolidated and standalone figures differ by less than ₹0.1 Cr in most lines, because the subsidiaries are immaterial.

Income Statement

Notes: FY2022–FY2025 revenue and EBITDA are from Infomerics releases (30 Mar 2023, 24 Apr 2024, 11 Jul 2025). FY2026 revenue and gross profit are from aggregator mirrors of the audited filing. The ₹24,365.02 lakh figure some outlets call "revenue" is total income. FY2026 EBITDA is company-reported on a consolidated basis; the company's FY2024 and FY2025 EBITDA on the same basis were ₹5.11 Cr and ₹10.80 Cr, against Infomerics' ₹4.53 Cr and ₹9.31 Cr. FY2022–FY2023 PBT, depreciation and interest are Screener whole-crore roundings. Company-reported EPS is lower than the Screener basis because the company deducts 12% preference dividends (₹68.28 lakh paid in FY2025) from profit attributable to equity holders. Revenue CAGR: FY2021–FY2026 (5-year) 22.5%, from ₹87.36 Cr in FY2021 (Infomerics). FY2022–FY2026 (4-year) 17.6%.

Commentary. Revenue has scaled consistently. Two step-ups stand out: FY2022 (+44%, post-COVID restocking and price inflation in acrylic monomers) and FY2025 (+41%, Tarapur volume growth plus export momentum, despite Dahej being offline for most of the year). FY2023–FY2024 was a plateau, as the company diverted capital to Dahej (CWIP rose to ₹47 Cr in FY2023) while legacy volumes stagnated. Margins tell the opposite story. EBITDA margin compressed from 7.4% (FY2021) to 3.3% (FY2024) as the Dahej build-out absorbed overheads, raw-material costs stayed elevated, and the February 2024 fire cut contribution from the higher-margin peroxide line. Recovery since FY2025 (4.8%), FY2026 (6.8%) and H1 FY2027 (6.6%) coincides with Dahej's restart and a richer salicylate/peroxide mix, per management's November 2025 commentary. Bottom-line quality is poor. FY2024 profit of ₹3.0 Cr was flattered by a tax credit and about ₹5 Cr of other income. FY2025 swung to a loss because a ₹1.29 Cr deferred-tax reversal more than absorbed a thin ₹0.36 Cr PBT, itself supported by a ₹2.62 Cr exceptional item linked to the Dahej insurance settlement. FY2026 is the first year in three where operating profit, not one-offs, drove the result. Interest costs (₹8.4 Cr) still consumed over half of EBITDA.

Half-Yearly Trend (consolidated)

Sources: Company press release 18 Nov 2025 (H1 FY2025, H1 FY2026, ₹ lakh converted); MarketsMojo and Screener (H2 FY2026, H1 FY2027; whole-crore roundings for H2 FY2025). H1 FY2027 revenue grew 56.9% YoY. Net profit rose from ₹0.19 Cr to ₹3.45 Cr. Trailing-twelve-month revenue to September 2026 is ₹304.3 Cr; TTM net profit is about ₹4.6 Cr; TTM EPS is ₹5.46 (Screener).

Balance Sheet

Sources: Screener.in (filing-derived; whole crores). Infomerics PRs. FY2025 Auditor's Report (inventory, cited as ₹41.37 Cr in one table and ₹41.27 Cr in another). Cash for FY2025 is "cash flow / balance of ₹10.93 Cr as on 31 Mar 2025" per Infomerics. Short-term versus long-term debt split for FY2026 is not publicly disclosed. As of the July 2025 rating, rated facilities comprised ₹33.18 Cr of term loans and GECL, ₹27.50 Cr of fund-based working capital (cash credit plus usance bill discounting), and ₹40.18 Cr of non-fund-based and proposed short-term lines. Goodwill: none disclosed. Net worth at 30 Sep 2026 rose to about ₹63 Cr after warrant conversions; borrowings were ₹78 Cr (Screener).

Net debt. Net debt is about ₹49 Cr for FY2025 (₹59.63 Cr debt less ₹10.93 Cr cash). For other years it cannot be computed because cash is not publicly disclosed.

Working capital. Gross current-asset days were 233 (FY2021), 206 (FY2022), about 185 (FY2023), about 284 (FY2024) and about 232 (FY2025), per Infomerics. Large creditor balances, including letters of credit, finance the cycle. Payable days of 176–213 explain a negative cash-conversion cycle despite high inventory.

Cash Flow

Source: Screener.in. FY2025 investing cash flow was positive because the ₹20.49 Cr insurance receipt (26 Mar 2025) offset Dahej reconstruction capex. Screener's free-cash-flow series is computed on gross capex, including insurance-funded rebuild, and has been negative for five consecutive years. Cumulative FY2022–FY2026 FCF is about –₹66 Cr. It was funded by debt (borrowings up about ₹23 Cr) and equity from promoter infusion and warrants (Infomerics notes ₹18.45 Cr infused by promoters over FY2024–FY2025).

Ratios

Sources and method: ROE and ROA computed by the analyst from Screener net worth and total assets and filing net profit. ROCE, days ratios and CCC from Screener. Current ratio, gearing and interest coverage from Infomerics (FY2022–FY2025). FY2026 interest coverage is analyst-computed (16.37 / 8.41). ROIC is not computed separately because the tax line is too distorted for a reliable NOPAT; Screener ROCE serves as the proxy. Definitional conflict: the company's FY2025 MD&A reports debt-equity of 2.66x and interest coverage of 0.97x, on definitions that include other liabilities and different profit measures, against 1.25x and 1.20x per Infomerics. Net debt / EBITDA: about 5.2x in FY2025 (₹48.7 Cr / ₹9.31 Cr); not computable for other years.

Trend synthesis. Returns on capital are structurally sub-par. A 10-year average ROE of about 4% (Screener) sits well below any reasonable cost of equity. The FY2026 ROCE recovery to 11% is the best since FY2020 and is the key inflection to monitor. Leverage peaked in FY2023–FY2024, during the Dahej build and fire. It improved via equity injections, then edged up again in FY2026 as borrowings rose ₹16 Cr. The heavy use of supplier credit and LCs (payable days of 176–213) is both a funding strength and a fragility, since any tightening of LC lines would strain liquidity quickly.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Group Entities

EntityRelationshipActivityFY2025 revenueFY2025 net profitSource

Ambani Orgochem Limited

Listed parent

Manufacturing (Tarapur and Dahej)

₹19,253.87 lakh (revenue from operations)

₹(92.08) lakh

FY2025 Directors' Report

Om Maruti Glasswool & Wirenetting Products Pvt Ltd

Subsidiary

Metal soaps (paint driers, FRP hardeners), per website

₹6.01 lakh

₹3.47 lakh

FY2025 Directors' Report (AOC-1)

Omega Woven Mills Pvt Ltd

Subsidiary

Neighbouring unit (land/facility)

₹6.00 lakh

₹3.18 lakh

FY2025 Directors' Report (AOC-1)

Results by Segment and Segment Margins & Growth (%)

SegmentFY2024FY2025FY2026

Specialty chemicals revenue (INR Cr)

136.20192.54240.74

YoY growth (%)

2.641.425.0

Share of total revenue (%)

100100100

Segment EBITDA (INR Cr)

4.539.3116.37

Segment EBITDA margin (%)

3.334.846.80

Segment pre-tax income (INR Cr)

0.200.364.10

Income Statement and Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025FY2026

Revenue from operations (INR Cr)

126.04132.78136.20192.54240.74

Total income incl. other income (INR Cr)

——136.68193.93243.65

Revenue growth YoY (%)

44.35.32.641.425.0

Gross profit (INR Cr)

————67.14

EBITDA (INR Cr)

7.308.584.539.3116.37

Depreciation and amortisation (INR Cr)

112.793.044

Finance costs (INR Cr)

3477.788.41

Exceptional items (INR Cr)

0002.62—

Profit before tax (INR Cr)

330.200.364.1

Net profit (INR Cr)

1.971.913.00-0.921.36

Net profit consolidated (INR Cr)

——3.04-0.851.33

EPS basic, Screener basis (INR)

3.062.974.25-1.201.78

EPS basic, company-reported (INR)

———-2.211.08

Dividend per equity share (INR)

00000

Gross margin (%)

————27.9

EBITDA margin (%)

5.796.463.334.846.80

PBT margin (%)

2.42.30.10.21.7

Net margin (%)

1.561.442.20-0.480.56

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Income Statement and Margin Analysis (%) (Half-Yearly)

MetricH1 FY2025H2 FY2025H1 FY2026H2 FY2026H1 FY2027

Revenue (INR Cr)

81.75112109.15133.09171.22

EBITDA excl. other income (INR Cr)

4.4867.928.4511.31

EBITDA margin (%)

5.465.47.166.426.65

Finance costs (INR Cr)

4353.865.28

Net profit (INR Cr)

-1.7810.191.143.45

EPS (₹, Screener)

-2.521.210.251.493.99

Balance Sheet

MetricFY2022FY2023FY2024FY2025FY2026

Total assets (INR Cr)

112137176208223

Net fixed assets incl. CWIP (INR Cr)

2966648186

Capital work in progress (INR Cr)

9478711

Cash and equivalents (INR Cr)

—5.85—10.93—

Total borrowings, Screener (INR Cr)

5352616076

Total debt, Infomerics (INR Cr)

52.8172.3860.7659.63—

Equity share capital (INR Cr)

66788

Reserves (INR Cr)

2426394444

Net worth (INR Cr)

3032465252

Tangible net worth, Infomerics (INR Cr)

30.8332.0745.1951.18—

Inventory (INR Cr)

———41.37—

Other liabilities incl. trade payables (INR Cr)

2954689795

Cash Flow and Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025FY2026

Operating cash flow (INR Cr)

-723-12120

Investing cash flow (INR Cr)

-11-38-12-8

Financing cash flow (INR Cr)

261114-38

Net change in cash (INR Cr)

7-5110-1

Free cash flow, Screener (INR Cr)

-19-16-13-9-9

Equity dividends paid (INR Cr)

00000

Preference dividends paid (INR Cr)

———0.68—

Buybacks (INR Cr)

00000

CFO / EBITDA (%)

-108282-2671251

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2022FY2023FY2024FY2025FY2026

ROE, net profit / avg net worth (%)

8.06.27.7-1.92.6

ROA, net profit / avg total assets (%)

2.11.51.9-0.50.6

ROCE, Screener (%)

992711

Current ratio (x)

1.291.011.151.01—

Debt / equity, Screener borrowings / net worth (x)

1.771.631.331.151.46

Gearing, Infomerics (x)

1.712.261.431.25—

Gross debt / EBITDA (x)

7.36.113.56.44.6

Interest coverage, EBITDA / interest (x)

2.152.290.671.201.95

Asset turnover, revenue / avg assets (x)

1.331.070.871.001.12

Debtor days

9377718076

Inventory days

757710010389

Payable days

63142194213176

Cash conversion cycle (days)

10512-22-30-11

Region Overview

RegionFY2025

Export revenue, FX earnings proxy (INR Cr)

76.44

Domestic revenue, derived (INR Cr)

116.10

Export share of revenue (%)

39.7

FX outgo (INR Cr)

0.26

Valuation Snapshot

MetricValueSource

Last price

₹175.10 (19 Oct 2026); ₹169.75–170 (16 Oct 2026)

ScanX; MarketsMojo; Screener

52-week range

₹94.90 – ₹175.10

ScanX; Screener

IPO price / listing price

₹66 / ₹66.65 (18 Jul 2018)

IPO Central

Return since IPO

About +165% at ₹175 (about 11.9% CAGR over 8.25 years)

Analyst calculation

Price CAGR (Screener)

1-year 21%; 3-year 10%; 5-year 11%

Screener (16 Oct 2026)

5-year price return (MarketsMojo)

+61.67%

MarketsMojo

Market capitalisation

₹147–156 Cr

Screener; ScanX; analyst

Valuation Multiples

MultipleAmbani OrgochemBasisSource

P/E (TTM)

About 32x at ₹175 (TTM EPS ₹5.46). Aggregators show 37.7x (Screener, ₹170) and 108–110x (MarketsMojo / ScanX, on FY2026 EPS)

TTM versus FY2026

Screener; ScanX; analyst

P/B

About 2.4x (₹175 / book value ₹72.9); 2.56–2.76x per aggregators

Sep 2026 book

Screener; MarketsMojo

EV/EBITDA

About 11.6x TTM (analyst: about ₹229 Cr EV on gross debt / ₹19.8 Cr TTM EBITDA); 12.5x per MarketsMojo

TTM

Analyst; MarketsMojo

EV/Sales

About 0.75x TTM; 0.83x per MarketsMojo

TTM

Analyst; MarketsMojo

Industry P/E

About 42x

Sector

MarketsMojo

Peer P/E

Fine Organic 38.2x; Atul 22.5x; Aarti Industries 34.4x; Pidilite 57.1x

Trailing

eduinvesting peer table

Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025FY2026

Dividend per equity share (INR)

00000

Promoter holding at year end (%)

63.5963.5957.9561.2561.25

Number of shareholders at year end

—210251281280

Capital Programmes

ProgrammeSizePriceOutcomeSource

FY2024 warrants

41.26 lakh

₹80

12.26 lakh converted (listed Nov 2023 – Jan 2024 and Nov 2024); 29.00 lakh forfeited (₹5.80 Cr to general reserve)

FY2025 Directors' Report; NSE circulars

FY2025 warrants

12.60 lakh

₹90

Allotted 27 Feb 2025; fully converted by 19 Aug 2026 (₹11.34 Cr gross)

NSE filing, 19 Aug 2026

FY2027 warrants (proposed)

43.925 lakh

₹100 (implied)

EGM 26 Oct 2026

NSE filings, 16 Oct 2026

Analyst Conclusions

Management guidance. Qualitative only. Management expects continued margin improvement, Dahej utilisation gains, a mix shift to salicylates and peroxides, and capacity additions at Tarapur. No numerical targets.

Consensus expectations. None; no coverage.

Run-rate reference (not guidance). H1 FY2027 annualised revenue is about ₹340 Cr. EBITDA margin is about 6.6%. Interest is about ₹10.6 Cr annualised.

Bull case.

  1. Operating leverage from Dahej. H1 FY2027 revenue (+57%) and net profit (₹3.45 Cr against ₹0.19 Cr) show the post-fire restart flowing to the bottom line. Each 100 bp of EBITDA margin on about ₹340 Cr of revenue adds about ₹3.4 Cr, roughly equal to H1 FY2027 net profit.

  2. Equity-funded deleveraging and capacity. The ₹43.9 Cr warrant raise could retire over half of ₹76 Cr of borrowings or fund the 4x salicylic and 2.25x acrylic expansions. Either path would lift interest coverage from about 2x toward 4x and lower the cost of capital.

  3. Structural niches. Solar-EVA crosslinkers, phthalate-free curing agents and salicylate UV filters align with fast-growing Indian demand pools. Licensed hazardous-chemistry capacity is a genuine barrier.

Bear case.

  1. Chronic low returns. A 10-year average ROE of about 4%, five years of negative FCF, and margins far below specialty peers (6.8% versus about 18% at Fineotex) suggest a commodity business wearing specialty labels.

  2. Dilution and governance. The warrants could add about 49% to the share count at ₹100, about 43% below the current price. The SME exemption, recurrent filing inconsistencies and serial warrant programmes (one largely forfeited) temper governance comfort.

  3. Execution and safety concentration. One fire cost a year of Dahej output. Phase 2 slipped twice. The valuation re-rating (P/B of about 2.4x; a 32% move in five days) prices in execution that has not yet been demonstrated on a full-year basis.

Catalysts and monitorables (next 12 months).

  • 26 Oct 2026 EGM: approval, allottee list (promoter participation?), and stated use of proceeds.

  • H2 FY2027 results (around May 2027): can EBITDA margin hold at or above 6.5% and net margin exceed 1.5% for a full year?

  • Commissioning evidence for Dahej Phase 2 and the Tarapur acrylic expansion.

  • Settlement of the Dahej loss-of-profit insurance claim.

  • Next Infomerics review (due around July 2026–2027): upgrade potential if leverage falls.

  • Working-capital trend, especially payable days, and any LC-line changes.

  • Disclosure quality: segment, export and capacity data in the next annual report.

Concluding analyst verdict. Ambani Orgochem is at an operational inflection, but not yet a financial one. Four facts anchor the bull narrative. Revenue has doubled in three years, from ₹136 Cr in FY2024 to a ₹304 Cr trailing run-rate. The Dahej peroxide and salicylate platform is back online after the February 2024 fire. EBITDA margin has recovered from 3.3% to about 6.6%. H1 FY2027 delivered the best half-year profit in the company's history. Management's strategic direction toward organic peroxides and salicylates is sound. These chemistries carry real barriers to entry and fit Indian demand themes in composites, solar, fragrance and personal care.

The quality of earnings, however, still lags the narrative. Interest absorbs about half of EBITDA. Free cash flow has been negative for five years. Ten-year average ROE of about 4% has never covered the cost of capital. Disclosure is thin, with no segment, product, customer or R&D data. Capacity figures are inconsistent across company sources. Governance is promoter-dominated under SME exemptions, and equity has been raised repeatedly through warrants. The proposed 43.9 lakh warrants at about ₹100 would materially dilute holders. They would, though, also repair the balance sheet. Whether they are value-accretive depends on undisclosed objects and allottees.

At about ₹175, the stock trades on roughly 32x trailing earnings, 2.4x book and about 11–12x EV/EBITDA. That is not demanding for a company growing revenue above 30%, provided margins keep expanding. It is expensive for a business whose sustainable net margin remains unproven above 1.5%. Our assessment is a speculative, execution-dependent turnaround. The investment case strengthens materially if three conditions hold: full-year FY2027 EBITDA margin above 7%, warrant proceeds directed to deleveraging or high-return capacity, and Dahej running incident-free at high utilisation. Absent these, the recent re-rating looks premature. Liquidity, at 280 shareholders and thin SME trading, adds a further discount.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameTitleIn role sinceAgeBackgroundSource

Rakesh Hasmukhlal Shah

Promoter, Managing Director

Board since 7 Mar 1996

56

Over three decades in the chemical industry; leads the company since 1996

MarketScreener; Infomerics; company website

Apooni Rakesh Shah

Promoter, Whole-time Director (listed as Chairperson by MarketScreener)

1 Apr 2018

57

Co-promoter; signatory on exchange filings (DIN 00503116)

MarketScreener; NSE filings

Paresh Harsuklal Shah

Chief Executive Officer

1 Apr 2018

—

Holds 1,100 shares (promoter group)

MarketScreener; Trendlyne

Bhavesh Babulal Pandya

Chief Financial Officer

1 Apr 2018

——

MarketScreener; FY2025 Directors' Report

Vaanie Dangi

Company Secretary and Compliance Officer

11 Sep 2023

——

MarketScreener; FY2025 Directors' Report

Dinesh More

Chief Administrative Officer

24 Aug 2013

——

MarketScreener

“—” = not publicly disclosed.

Board of Directors

NameCategoryAppointedAgeSource

Apooni Rakesh Shah

Executive (Whole-time Director), promoter

1 Apr 2018

57

MarketScreener

Rakesh Hasmukhlal Shah

Executive (Managing Director), promoter

7 Mar 1996

56

MarketScreener

Prakash Anna Mahanwar

—

1 Apr 2018

58

MarketScreener

Bhavin Jitendra Patel

Non-executive (additional director Feb 2024; regularised 30 Apr 2024)

19/20 Feb 2024

30

MarketScreener; Directors' Report

Neerajkumar Amarjeet Pandey

Non-executive; retired by rotation at the 39th AGM and sought reappointment

19/20 Feb 2024

54

MarketScreener; Directors' Report

Rajesh Vasudeo Desai

—

3 Dec 2025

68

MarketScreener

Mahesh Shrirang Jagdale

—

23 Jul 2026

—

MarketScreener

“—” = not publicly disclosed.

Directors' Remuneration

PersonFY2026 total compensationSource

"CEO" (Simply Wall St designation; likely the Managing Director)

₹1.3 million (about ₹13 lakh)

Simply Wall St, 18 Oct 2026

Shareholding Trend

Holder categoryMar 2021Sep 2022Mar 2024Mar 2025Mar 2026Jun 2026Sep 2026

Promoter and promoter group (%)

72.6763.5957.9561.2561.2554.3052.59

Public (%)

27.3336.4142.0538.7538.7545.7047.41

Number of shareholders

—212251281280284280

Major Shareholders

HolderStakeAs ofSource

Rakesh Hasmukhlal Shah (promoter)

48.94% (43,64,721 shares)

Aug 2026

MarketsMojo; promoter disclosure Jul 2026

Apooni Rakesh Shah (promoter)

About 3.5% (3,14,738 shares; 4.11% pre-dilution)

Nov 2024 share count

Trendlyne

MNS Securities Limited (public)

7.85% (7,00,000 shares)

19 Aug 2026

NSE filing

Chintan Vidyut Shah (public)

1.07% (95,000 shares)

19 Aug 2026

NSE filing

Jyotindra Ramniklal Doshi (promoter group)

About 0.11% (10,000 shares)

Nov 2024 share count

Trendlyne

Paresh H. Shah (promoter group / CEO)

About 0.01% (1,100 shares)

Nov 2024 share count

Trendlyne

Bodies corporate (aggregate)

13.55% (10 holders)

Nov 2024

Trendlyne

Competitive Landscape

Peer Comparison

PlatformCompetitorsTypeRelative positioning

Organic peroxides

Nouryon (India operations; reported India peroxide expansion), Arkema, United Initiators, NOF Corporation, Pergan, Chinese producers (Jiangsu Yuanyang, Zibo Zhenghua)

Global majors and Chinese exporters

Ambani is a small domestic challenger competing on local supply, short lead times and price for MEKP, BPO and solar-EVA grades

Salicylic acid and salicylates

Novacyl (Seqens), Alta Laboratories (India), Chinese salicylic-acid producers; aroma-chemical producers such as Oriental Aromatics and Privi Speciality Chemicals for esters

Global and Indian

Small-capacity entrant (about 50 t/month); import-substitution play

Acrylic emulsions, binders, adhesives

Pidilite Industries, Nikhil Adhesives, BASF India, Dow, Synthomer, Jubilant Agri & Consumer Products

Indian majors and multinationals

Price-taker in a fragmented market; niche in paper, textile and carpet binders

Textile auxiliaries

Fineotex Chemical, Archroma, Huntsman, Sarex

Indian and multinational

Small, GOTS/ZDHC-certified niche supplier

Paint driers / metal carboxylates

Borchers (Milliken), Umicore, regional Indian producers

Global and unorganised domestic

Broad grade range incl. lead-free systems; limited scale

Peer Comparison FY2026

CompanyRevenue FY2026YoY growth (%)EBITDA margin (%)Net profitNet margin (%)R&D intensity

Ambani Orgochem

240.7425.06.81.360.6

Not disclosed (nil reported FY2025)

Fineotex Chemical

772.244.817.7108.814.1—

Fine Organic Industries

2,482.54.9—41716.8—

Pidilite Industries

14,86711.1—2,47116.6—

“—” = not publicly disclosed.

Company Snapshot

$27.8M

Revenue

124

Employees

1985

Founded

Mumbai, India

Headquarters

SWOT Analysis

Strengths

  • Sustained top-line compounding. Five-year revenue CAGR of 22.5% (₹87.36 Cr in FY2021 to ₹240.74 Cr in FY2026), with H1 FY2027 up 57% YoY (Infomerics; MarketsMojo).
  • Hazard-chemistry capability. About 39 organic-peroxide grades plus salicylic acid. The company holds Dahej environmental clearance (GPCB CTE, 6 May 2022), a scarce asset (FY2026 presentation).
  • Export franchise. FX earnings of ₹76.44 Cr in FY2025, about 40% of revenue, across 40+ countries (FY2025 Directors' Report; FY2026 presentation).
  • Promoter commitment. Promoters infused ₹18.45 Cr of equity over FY2024–FY2025, with zero pledging (Infomerics July 2025; MarketsMojo).
  • Catalogue breadth. Over 100 SKUs across peroxides, salicylates, driers and emulsions (company website), enabling cross-sell across about 10 end markets.
  • Certifications. ISO 9001/14001/45001, GOTS and ZDHC support export textile supply chains (FY2025 MD&A).

Weaknesses

  • Thin margins. EBITDA margin of 3.3–6.8% over FY2022–FY2026, against 17.7% at Fineotex (Infomerics; S&P data).
  • Weak returns. 10-year average ROE of about 4%; FY2026 ROE 2.6% (Screener; analyst computation).
  • Persistent negative FCF. Free cash flow negative for five straight years, cumulative about –₹66 Cr (Screener).
  • Leverage and coverage. Gross debt / EBITDA of 4.6x and interest coverage of 1.95x in FY2026. Debt-service coverage was below 1x in FY2025 (Infomerics).
  • Earnings quality. Profits in FY2024–FY2025 relied on tax credits, other income and an exceptional item. FY2025 PBT was only ₹0.36 Cr (Directors' Report).
  • Disclosure gaps. No segment, product or customer data. Reported capacities conflict across sources (15,840 MTPA versus 24,000 t versus about 50,000 t). No R&D disclosure.

Opportunities

  • Capacity expansions. Acrylic capacity +125% (2,000 → 4,500 t/month) and salicylic acid 4x (50 → 200 t/month) (FY2026 presentation).
  • Solar EVA crosslinkers. TBEC/TAEC grades are positioned for India's solar-module build-out (product catalogue).
  • Dahej utilisation upside. The plant was still at partial capacity in November 2025, so operating leverage remains (press release).
  • China+1 and import substitution. Cited in the FY2025 MD&A as structural tailwinds.
  • Pending insurance recovery. The loss-of-profit claim for the Dahej fire was still outstanding (FY2025 Directors' Report).
  • Deleveraging via equity. The ₹43.9 Cr warrant raise, if fully converted, roughly equals 56% of FY2026 borrowings of ₹76 Cr (NSE filing; Screener).

Threats

  • Single-site process-safety risk. The 10 Feb 2024 Dahej fire halted the plant for about 12 months (company disclosures).
  • Chinese competition. Global peroxide and salicylic-acid markets include large Chinese producers (Global Market Insights player list).
  • Raw-material volatility. Acrylic monomers, styrene and phenol derivatives with no backward integration (Infomerics cites limited pricing power).
  • Credit tightening. Heavy reliance on ₹37 Cr of LC lines and payable days of 176–213 (Infomerics; Screener).
  • Dilution. The proposed warrants equal about 49% of current shares (NSE filing, 16 Oct 2026).
  • Name confusion. Headline association with "Ambani" group news (e.g., the March 2026 ED property freeze linked to Anil Ambani entities) can drive speculative trading unrelated to fundamentals (ScanX news feed).

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
29 May 2025FY2025 audited results: revenue ₹192.54 Cr (+41%), net loss ₹0.92 Cr Directors' Report; eduinvestingGrowth intact; bottom line hit by deferred-tax reversal
29 May 2025Unmodified audit opinion with emphasis of matter on Dahej fire insurance claim FY2025 Auditor's ReportHighlights estimation risk on pending loss-of-profit claim
11 Jul 2025Infomerics reaffirms IVR BB+/Stable and IVR A4+; GECL 1.0 withdrawn after repaymentSub-investment-grade but stable credit
4 Sep 2025FY2025 Annual Report issued Directors' ReportDiscloses ₹76.44 Cr FX earnings, no R&D spend
30 Sep 202539th AGM; scrutinizer report filed NSE archiveRoutine resolutions incl. director reappointment
14 Nov 2025Board approves H1 FY2026 results eduinvesting corporate actions—
18 Nov 2025H1 FY2026 release: revenue ₹109.15 Cr (+33.5%), EBITDA ₹7.92 Cr (+76.8%), net profit ₹0.19 Cr Company press releaseFirst evidence of Dahej-led margin recovery
19 Nov 2025Syndicated coverage of H1 results (ANI / The Tribune advertorial)Increased retail visibility
3 Dec 2025Rajesh Vasudeo Desai joins board MarketScreenerBoard strengthening
FY2026 (date not specified)11,38,080 preference shares redeemed (₹1.14 Cr); capital redemption reserve created ScanXLowers fixed-dividend burden
Mar 2026Dahej Phase 2 target date (per Infomerics)Completion not confirmed in retrieved sources
21 May 2026FY2026 audited results: total income ₹243.65 Cr (+25.6%), net profit ₹1.36 Cr standalone Results filing via ScanXReturn to profitability
12 Jun 202612% preference dividend and redemption of 28,45,200 preference shares (₹2.85 Cr) approved ScanXContinued capital-structure simplification
Apr–Jun 2026About 9.8 lakh shares issued on warrant conversion (inferred); promoter stake to 54.30% Screener shareholdingEquity infusion; dilution
1 Jul 2026Promoter shareholding disclosure: Rakesh Shah 43.64 lakh shares, no encumbrance eduinvestingNo pledging
8 Jul 2026Q1 FY2027 update: highest-ever quarterly revenue, +49% YoY, +13% QoQ ScanXDemand and utilisation recovery post-fire
23 Jul 2026Mahesh S. Jagdale joins board MarketScreenerBoard change
19 Aug 20262,80,190 shares allotted on warrant conversion; MNS Securities to 7.85% NSE filingCompletes FY2025 warrant programme
4 Sep 2026FY2026 Annual Report dispatched; 40th AGM notice NSE filingChairman cites "super-specialty" priority
8 Sep 2026FY2026 investor presentation coverage: capacity expansions, 40+ export countries MultibaggFirst detailed capacity disclosure
Sep 2026First earnings call held ScreenerImproved disclosure
28 Sep 2026Board considers fund raising MultibaggPrecursor to warrant issue
15 Oct 2026H1 FY2027 results: revenue ₹171.22 Cr (+57% YoY), EBITDA ₹11.31 Cr, net profit ₹3.45 Cr MarketsMojo; ScreenerBest half-year on record
15 Oct 2026Structured Digital Database compliance certificate (no non-compliance); Regulation 27(2) non-applicability filing Screener announcementsRoutine compliance
16 Oct 2026Warrant issue resized to 43,92,500 (₹43.925 Cr); one allottee excluded; corrigendum to EGM notice NSE filings via ScreenerLarge prospective equity raise
16–19 Oct 2026Share price hits 52-week high (₹169.75 on 16 Oct; ₹175.10 on 19 Oct); 5-day gain about 32% MarketsMojo; ScanXRe-rating on results and fund raise
26 Oct 2026 (scheduled)EGM on preferential warrant issue NSE filingsApproval gate for ₹43.9 Cr raise

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

5 charts
Income Statement: Revenue & Gross Profit: Revenue from operations rose from INR 1,260.4 Mn in FY2022 to INR 2,407.4 Mn in FY2026.
AMBANI ORGANICS LT — Income Statement: Revenue & Gross Profit
Series (INR Mn)FY2022FY2023FY2024FY2025FY2026
Revenue from operations1,260.41,327.81,3621,925.42,407.4
Gross profit————671.4

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.